Copyright
©The Author(s) 2018.
World J Gastrointest Oncol. Dec 15, 2018; 10(12): 496-504
Published online Dec 15, 2018. doi: 10.4251/wjgo.v10.i12.496
Published online Dec 15, 2018. doi: 10.4251/wjgo.v10.i12.496
Table 1 Baseline characteristics, n (%)
| Group A (n = 54) | Group B (n = 57) | P value | |
| Gender | 0.693 | ||
| Male | 35 (64.8) | 39 (68.4) | |
| Female | 19 (35.2) | 18 (31.6) | |
| Average age (yr) | 43.6 ± 6.9 | 44.3 ± 5.2 | 0.697 |
| Pathogenesis | 0.788 | ||
| Hepatitis B | 35 (64.8) | 38 (66.7) | |
| Hepatitis C | 9 (16.7) | 12 (21) | |
| Alcoholic | 5 (9.3) | 2 (3.5) | |
| Cholestasis | 2 (3.7) | 1 (1.8) | |
| Autoimmunity | 1 (1.8) | 2 (3.5) | |
| Others | 2 (3.7) | 2 (3.5) | |
| Child–Pugh classification | 0.705 | ||
| A | 25 (46.3) | 24 (42.1) | |
| B | 29 (53.7) | 33 (57.9) | |
| C | 0 (0) | 0 (0) | |
| Albumin (g/L) | 34.5 ± 7.5 | 31.5 ± 11.5 | 0.880 |
| Alanine aminotransferase (U/L) | 62.5 ± 46.5 | 49.5 ± 37.5 | 0.396 |
| Glutamyl transpeptidase (U/L) | 73 ± 66 | 74 ± 62 | 0.647 |
| Na+ | 143.5 ± 8.5 | 140 ± 7 | 0.104 |
| K+ | 4.12 ± 1.08 | 4.75 ± 1.05 | 0.883 |
| Direct bilirubin (μmol/L) | 29.8 ± 25.2 | 24.5 ± 18.5 | 0.299 |
| Aspartate aminotransferase (U/L) | 39 ± 30 | 49 ± 39 | 0.349 |
| MELD score | 11.96 ± 1.68 | 12.76 ± 2.47 | 0.145 |
| Ascites | 0.624 | ||
| Yes | 11 (20.4) | 9 (15.8) | |
| No | 43 (79.6) | 48 (84.2) | |
| Size of liver cancer (cm) | 0.788 | ||
| ≤ 5 | 14 (25.9) | 17 (29.8) | |
| 5-8 | 31 (57.4) | 29 (50.9) | |
| > 8 | 9 (16.7) | 11 (19.3) | |
| No. of liver tumors | 0.834 | ||
| 1 | 28 (51.9) | 32 (56.1) | |
| 2 or 3 | 19 (35.2) | 17 (29.8) | |
| > 3 | 7 (12.9) | 8 (14.1) |
Table 2 Differences of portosystemic pressure gradient in the two groups before and after operation
| PPG before operation (mmHg) | PPG after operation (mmHg) | t | df | P value | |
| Group A | 26.9 ± 6.22 | 13.6 ± 6.4 | 18.11 | 53 | < 0.0001 |
| Group B | 26.77 ± 6.25 | 15.1 ± 7.2 | 17.10 | 56 | < 0.0001 |
Table 3 Time-to-event outcomes
| Group A (n = 54) | Group B (n = 57) | P value | |
| Rate of stent stenosis | < 0.05 | ||
| 6 mo | 18.5 | 43.9 | |
| 12 mo | 55.6 | 82.5 | |
| 24 mo | 83.3 | 96.5 | |
| Survival rate | < 0.05 | ||
| 6 mo | 85.2 | 50.9 | |
| 12 mo | 42.6 | 10.5 | |
| 24 mo | 22.2 | 0 |
Table 4 Multivariate analysis of factors associated with postoperative outcomes
| Hazard ratio | 95%CI | P value | |
| Pathogenesis | 1.227 | 0.773–1.948 | 0.385 |
| Albumin (g/L) | 1.266 | 0.829–1.932 | 0.275 |
| Alanine aminotransferase (U/L) | 1.222 | 0.798–1.872 | 0.357 |
| Glutamyl transpeptidase (U/L) | 0.821 | 0.509–1.224 | 0.419 |
| Direct bilirubin (μmol/L) | 2.262 | 0.270–18.96 | 0.452 |
| Aspartate aminotransferase (U/L) | 1.270 | 0.800–2.017 | 0.311 |
| No. of liver tumors | 1.238 | 0.232–19.41 | 0.330 |
- Citation: Wu YF, Wang T, Yue ZD, Zhao HW, Wang L, Fan ZH, He FL, Liu FQ. Stents combined with iodine-125 implantation to treat main portal vein tumor thrombus. World J Gastrointest Oncol 2018; 10(12): 496-504
- URL: https://www.wjgnet.com/1948-5204/full/v10/i12/496.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v10.i12.496
